Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory DisordersDavid Harrison, Alan P. Watt, Andy Billinton et al.|Journal of Medicinal Chemistry|2023Cited by 62
Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushingTaku Sakurai, Matt Barnes, Richard Davenport et al.|European Journal of Pharmacology|2014Cited by 54
Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796Peter Thornton, Alan P. Watt, Valérie Reader et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 51
Myocardial Hypertrophy Resulting from Low Dosage Isoproterenol Administration in RatsE. L. Alderman, David Harrison|Experimental Biology and Medicine|1971Cited by 49
Engineering transglycosidase activity into a GH51 α-l-arabinofuranosidaseFaten Arab‐Jaziri, Michael O’Donohue, Bastien Bissaro et al.|New Biotechnology|2013Cited by 35